Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Depreciation and Depletion (2017 - 2025)

Rockwell Medical (RMTI) has disclosed Depreciation and Depletion for 9 consecutive years, with $400000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation and Depletion changed 0.0% year-over-year to $400000.0, compared with a TTM value of $400000.0 through Sep 2025, down 75.0%, and an annual FY2024 reading of $400000.0, down 66.67% over the prior year.
  • Depreciation and Depletion was $400000.0 for Q3 2025 at Rockwell Medical, roughly flat from $400000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $400000.0 in Q3 2023 and bottomed at -$800000.0 in Q4 2024.
  • Average Depreciation and Depletion over 5 years is $214105.3, with a median of $200000.0 recorded in 2021.
  • The sharpest move saw Depreciation and Depletion surged 300.0% in 2023, then crashed 300.0% in 2024.
  • Year by year, Depreciation and Depletion stood at $168000.0 in 2021, then grew by 19.05% to $200000.0 in 2022, then skyrocketed by 100.0% to $400000.0 in 2023, then plummeted by 300.0% to -$800000.0 in 2024, then surged by 150.0% to $400000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for RMTI at $400000.0 in Q3 2025, $400000.0 in Q2 2025, and $400000.0 in Q1 2025.